VictorGurewichMD

Internal Medicine • Cambridge, MA

Cardiology

Professor of Medicine, Mt. Auburn Hospital

Join to view full profile

Dr. Gurewich is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Gurewich's full profile

Already have an account?

Office
300 Mount Auburn St
305
Cambridge, MA 02138
Phone+1 617-661-0567

Fax+1 617-876-0524

Education & Training

Boston VA Healthcare System (Brockton-West Roxbury)Fellowship, Cardiovascular Disease, 1960 - 1961
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1959 - 1960
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1956 - 1957
Beth Israel Deaconess Medical CenterInternship, Transitional Year, 1955 - 1956
Harvard Medical SchoolClass of 1955

Certifications & Licensure

MA State Medical License 1960 - 2023
American Board of Internal Medicine Internal Medicine

Publications & Presentations

PubMed

6 citations
Dual thrombolytic therapy with mutant pro-urokinase and small bolus alteplase for ischemic stroke (DUMAS): study protocol for a multicenter randomized controlled phase...
Nadinda A M van der Ende, Bob Roozenbeek, Lucas E M Smagge, Sven P R Luijten, Leo A M Aerden
Trials. 2022-08-09
2 citations
Fibrinolysis: a Misunderstood Natural Defense Whose Therapeutic Potential Is Unknown
Victor Gurewich
Cardiovascular Drugs and Therapy. 2019-12-01
1 citations
A first-in-human study of DS-1040, an inhibitor of the activated form of thrombin-activatable fibrinolysis inhibitor, in healthy subjects: comment.
Victor Gurewich, Ralph Pannell
Journal of Thrombosis and Haemostasis. 2017-08-11

Press Mentions

FDA Gives Clearance for Drug to Treat Thrombotic DiseasesSeptember 24th, 2024
Thrombolytic Science Granted US Patent on Novel Clot Dissolving Therapy, Complementing Patent Protection in Europe, Japan, China, Hong Kong, Mexico & CISOctober 29th, 2021
TSI Reports Enrollment of First 10 Patients in Its Phase 2 Ischemic Stroke Clinical Trial and Completion of Its Phase 2 Study Protocol in Myocardial InfarctionOctober 30th, 2019
Join now to see all

Grant Support

Purification And Properties Of High Affinity UrokinaseNational Heart, Lung, And Blood Institute1985–1986